文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

感染性休克早期目标导向治疗效应的异质性:两项国际多中心试验的二次分析

Heterogeneity in the Effect of Early Goal-Directed Therapy for Septic Shock: A Secondary Analysis of Two Multicenter International Trials.
PubMed 文献 · Crit Care Med · 2024-10-23
一句话结论两项多中心RCT二次分析显示,EGDT对感染性休克的疗效存在个体异质性,部分患者可能获益(第5五分位绝对风险差12%),部分可能受损(第1五分位绝对风险差-8%)。

该研究对ARISE和ProCESS两项多中心RCT的站点进行随机拆分,建立推导队列和验证队列,用机器学习模型预测个体绝对风险差(iARD),并在验证队列中检验治疗效应异质性(HTE)。局部线性随机森林模型预测iARD表现最佳,验证队列中iARD预测与治疗的交互作用P<0.001,证实HTE存在。按预测iARD分组后,第1五分位绝对风险差为-8%(95%CI -19%至4%),相对风险降低1.34(0.89-2.01),提示EGDT可能有害;第5五分位绝对风险差为12%(95%CI 1%至23%),相对风险降低0.64(0.42-0.96),提示EGDT可能获益。治疗前白蛋白对HTE贡献最大,各EGDT组分分析未得出结论。

要点

  • 在ARISE和ProCESS两项多中心RCT的验证队列中,iARD预测与治疗的交互作用P<0.001,证实EGDT疗效存在异质性。
  • 按预测iARD分组,第1五分位绝对风险差-8%(95%CI -19%至4%),相对风险降低1.34(0.89-2.01),提示EGDT可能有害。
  • 第5五分位绝对风险差12%(95%CI 1%至23%),相对风险降低0.64(0.42-0.96),提示EGDT可能获益。
  • 治疗前白蛋白对治疗效应异质性贡献最大。
  • 对EGDT各单独组分的分析未得出结论。

适用人群与场景

  • 来自澳大利亚、新西兰、香港、芬兰、爱尔兰共和国和美国的81个中心,因严重脓毒症或感染性休克就诊于急诊科的成年患者。

研究设计与关键结果

  • 研究设计:对ARISE和ProCESS两项多中心RCT行二次分析,将研究站点随机拆分为推导队列和验证队列,用机器学习模型预测90天死亡率的个体绝对风险差(iARD)。
  • 模型性能:局部线性随机森林模型在预测iARD方面表现最佳。
  • 主要结果:验证队列中iARD预测与治疗的交互作用P<0.001,证实存在治疗效应异质性(HTE)。
  • 按预测iARD五分位分组:第1五分位绝对风险差-8%(95%CI -19%至4%),相对风险降低1.34(0.89-2.01),提示EGDT可能有害;第5五分位绝对风险差12%(95%CI 1%至23%),相对风险降低0.64(0.42-0.96),提示EGDT可能获益。
  • 敏感性分析显示相似结果。
  • 治疗前白蛋白对HTE贡献最大。
  • 对EGDT各单独组分的分析未得出结论。

证据类型、等级与局限

  • 证据类型:两项多中心随机对照试验(ARISE和ProCESS)的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,感染性休克患者对EGDT的治疗反应存在异质性,部分患者可能获益而部分可能受损;患者特征(包括白蛋白)在识别HTE方面最重要。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: The optimal approach for resuscitation in septic shock remains unclear despite multiple randomized controlled trials (RCTs). Our objective was to investigate whether previously uncharacterized variation across individuals in their response to resuscitation strategies may contribute to conflicting average treatment effects in prior RCTs.

DESIGN: We randomly split study sites from the Australian Resuscitation of Sepsis Evaluation (ARISE) and Protocolized Care for Early Septic Shock (ProCESS) trials into derivation and validation cohorts. We trained machine learning models to predict individual absolute risk differences (iARDs) in 90-day mortality in derivation cohorts and tested for heterogeneity of treatment effect (HTE) in validation cohorts and swapped these cohorts in sensitivity analyses. We fit the best-performing model in a combined dataset to explore roles of patient characteristics and individual components of early goal-directed therapy (EGDT) to determine treatment responses.

SETTING: Eighty-one sites in Australia, New Zealand, Hong Kong, Finland, Republic of Ireland, and the United States.

PATIENTS: Adult patients presenting to the emergency department with severe sepsis or septic shock.

INTERVENTIONS: EGDT vs. usual care.

MEASUREMENTS AND MAIN RESULTS: A local-linear random forest model performed best in predicting iARDs. In the validation cohort, HTE was confirmed, evidenced by an interaction between iARD prediction and treatment ( p < 0.001). When patients were grouped based on predicted iARDs, treatment response increased from the lowest to the highest quintiles (absolute risk difference [95% CI], -8% [-19% to 4%] and relative risk reduction, 1.34 [0.89-2.01] in quintile 1 suggesting harm from EGDT, and 12% [1-23%] and 0.64 [0.42-0.96] in quintile 5 suggesting benefit). Sensitivity analyses showed similar findings. Pre-intervention albumin contributed the most to HTE. Analyses of individual EGDT components were inconclusive.

CONCLUSIONS: Treatment response to EGDT varied across patients in two multicenter RCTs with large benefits for some patients while others were harmed. Patient characteristics, including albumin, were most important in identifying HTE.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Shah FA, Talisa VB, Chang CH, et al. Heterogeneity in the Effect of Early Goal-Directed Therapy for Septic Shock: A Secondary Analysis of Two Multicenter International Trials. Crit Care Med. 2024. PMID: 39440873. doi:10.1097/CCM.0000000000006463

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。